 Kalvista Pharmaceuticals Incs NASDAQ: KALV oral plasma kallikrein inhibitor, KVD900, has reduced the use of rescue medication in patients suffering swelling attacks associated with hereditary angioedema HAE, a disorder that results in recurrent episodes of severe swelling that most commonly affects the arms, legs, face, intestinal tract, and airway and is usually not itchy. The phase 2 clinical trial enrolled 53 adult HAE patients who had experienced three attacks in the 90 days before recruitment. 